CompletedPhase 2NCT00274924
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eastern Cooperative Oncology Group
- Principal Investigator
- Lode J. Swinnen, MD, MDSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Intervention
- filgrastim(biological)
- Enrollment
- 100 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2006 – 2019
Study locations (30)
- Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
- Front Range Cancer Specialists, Fort Collins, Colorado, United States
- Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- Rush-Copley Cancer Care Center, Aurora, Illinois, United States
- St. Joseph Medical Center, Bloomington, Illinois, United States
- Graham Hospital, Canton, Illinois, United States
- Memorial Hospital, Carthage, Illinois, United States
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
- Eureka Community Hospital, Eureka, Illinois, United States
- Evanston Northwestern Healthcare - Evanston Hospital, Evanston, Illinois, United States
- Galesburg Clinic, PC, Galesburg, Illinois, United States
- Galesburg Cottage Hospital, Galesburg, Illinois, United States
- Mason District Hospital, Havana, Illinois, United States
- Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00274924 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic